Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q1 2017 · 10-Q
Revenue$56.67M$56.67M−4.5% vs Q1 2016 Net Income$893.00K$893.00K−64.1% vs Q1 2016 EPS Diluted$0.02$0.02−60.0% vs Q1 2016 Gross Profit$22,807,000−8.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flow$22,398,000+60.8% Free Cash Flowderived$15,131,000+51.6% Margins · derivedGross margin40.2%−1.7 pt vs Q1 2016
Operating margin2.5%−4.4 pt vs Q1 2016
Net margin1.6%−2.6 pt vs Q1 2016
ended Mar 31, 2017 · filed May 10, 2017 · 40 d after period end